JPX · 4588.T
Oncolys BioPharma Inc.
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
Loading market information…
JPX · 4889.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Renascience Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Renascience Inc.’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Renascience Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:02 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
¥2,712+¥119 (+4.59%)
FALCO HOLDINGS Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 8.5% below the high.
¥192-¥8 (-4.0%)
CYBERDYNE Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.29% below the high.
¥629-¥138 (-17.99%)
Japan Tissue Engineering Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.15% below the high.
¥491+¥4 (+0.82%)
Kanamic Network Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 15.78% below the high.
¥635-¥1 (-0.16%)
Pharma Foods International Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 23.12% below the high.
¥749-¥17 (-2.22%)
CanBas Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 24.42% below the high.
¥122-¥4 (-3.17%)
ReproCELL Incorporated’s quoted price sits in the lower half of its reported 52-week range, 40.2% below the high.
